Lacosamide helps prevent primary generalized tonic-clonic seizures in some with epilepsy

Reuters Health - 28/09/2020 - Lacosamide can reduce the frequency of primary generalized tonic-clonic seizures (PGTCS) in patients with idiopathic generalized epilepsy (IGE) who receive one to three concomitant anti-epileptic drugs, a randomized trial shows. Compared with placebo, treatment with lacosamide significantly lowered the risk of a second PGTCS over the 24-week treatment period, researchers report in the Journal of Neurology, Neurosurgery and Psychiatry. The phase 3, double-blind trial also found that lacosamide (Vimpat, UCB Pharma) was generally safe when used as adjunct therapy in pediatric and adult patients. The drug is approved for the treatment of partial-onset seizures in patients 4 years and older. Lead author Dr. David Vossler of the University of Washington's Department of Neurology said in a prepared statement sent to Reuters that the trial "demonstrated that by adding lacosamide to existing anti-seizure medications, IGE patients with unc...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 28 September, 202022 October, 2020